Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2364163 Target Snapshot

Complement C5 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
13Compounds
25Assays
4Approved Drugs
12.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Complement C5 shows approved-linked disease relevance led by paroxysmal nocturnal hemoglobinuria. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P01031. Start with paroxysmal nocturnal hemoglobinuria, then reuse UniProt P01031 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with paroxysmal nocturnal hemoglobinuria, then reuse UniProt P01031 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 6 linked drugs
Open source guide
Disease program
paroxysmal nocturnal hemoglobinuria

Complement C5 shows approved-linked disease relevance led by paroxysmal nocturnal hemoglobinuria. 5 more disease programs remain visible in the same review block. 6 linked drugs remain visible in the same block.

Start review with paroxysmal nocturnal hemoglobinuria because it currently carries approved-linked support. Linked drugs include CROVALIMAB, ECULIZUMAB, NOMACOPAN, POZELIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 6 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Complement C5 as ChEMBL target CHEMBL2364163, mapped to UniProt P01031. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Complement C5
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2364163
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P01031
Complement C5
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Complement C5 is the right protein anchor across sources, using UniProt P01031 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why paroxysmal nocturnal hemoglobinuria is currently framed as approved-linked support. It currently carries 6 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameComplement C5
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP01031
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelComplement C5
UniProt AccessionP01031
Component TypeProtein
Sequence Length1676 aa

Complement C5

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Complement C5, mapped to UniProt P01031. Sequence length is 1676 aa.

Mapped IDP01031
Review nameComplement C5
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Complement C5 shows approved-linked disease relevance led by paroxysmal nocturnal hemoglobinuria. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
paroxysmal nocturnal hemoglobinuria
6 linked drugs · 6 direct · 6 efficacy
Linked drugCROVALIMAB
Linked drugECULIZUMAB
Linked drugNOMACOPAN
Linked drugPOZELIMAB
Approved-linked Approved
Myasthenia gravis
5 linked drugs · 5 direct · 5 efficacy
Linked drugECULIZUMAB
Linked drugPOZELIMAB
Linked drugRAVULIZUMAB
Linked drugZILUCOPLAN
Approved-linked Approved
acquired paroxysmal nocturnal hemoglobinuria
3 linked drugs · 3 direct · 3 efficacy
Linked drugCROVALIMAB
Linked drugPOZELIMAB
Linked drugZILUCOPLAN
Approved-linked Approved
atypical hemolytic-uremic syndrome
3 linked drugs · 3 direct · 3 efficacy
Linked drugCROVALIMAB
Linked drugECULIZUMAB
Linked drugRAVULIZUMAB
Approved-linked Approved
atrophic macular degeneration
2 linked drugs · 2 direct · 2 efficacy
Linked drugAVACINCAPTAD PEGOL SODIUM
Linked drugTESIDOLUMAB
Approved-linked Approved
hemolytic-uremic syndrome
2 linked drugs · 2 direct · 2 efficacy
Linked drugECULIZUMAB
Linked drugRAVULIZUMAB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with paroxysmal nocturnal hemoglobinuria because it currently carries approved-linked support. Linked drugs include CROVALIMAB, ECULIZUMAB, NOMACOPAN, POZELIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseparoxysmal nocturnal hemoglobinuria
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
Assay Mix

Activity Type Distribution

IC504.0
KD8.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2203296 6.68 IC50 210.0 Preclinical
CHEMBL2204196 6.36 IC50 440.0 Preclinical
CHEMBL15770 6.24 Kd 570.0 Approved
CHEMBL1316 6.24 Kd 580.0 Approved
CHEMBL4756677 6.21 IC50 620.0 Preclinical
CHEMBL1071 6.19 Kd 640.0 Approved
CHEMBL5594178 6.16 Kd 700.0 Preclinical
CHEMBL81 6.15 Kd 710.0 Approved
CHEMBL5594087 6.09 Kd 820.0 Preclinical
Distribution

pChEMBL Value Distribution

0
5.0
0
5.5
10
6.0
1
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

RALOXIFENE
CHEMBL81
Approved 1997
Properties Compare Identifier
OXAPROZIN
CHEMBL1071
Approved 1992
Properties Compare Identifier
CARPROFEN
CHEMBL1316
Approved 1987
Properties Compare Identifier
SULINDAC
CHEMBL15770
Approved 1978
Properties Compare Identifier
Assay Landscape

Assay Landscape

25
Total Assays
9
Tested Compounds
1
Assay Types
Binding — 25 assays, 9 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 24 6 6.1
cell-free format 1 3 6.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine